

Appl. No. 09/673,707
Amdt. dated October 12, 2004
Reply to Office Action of September 15, 2004

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity to the CD4 binding site of gp120 of 3B3 and a minimum binding affinity to gp-120 of 3B3, wherein said immunotoxin specifically binds to and kills mammalian cells infected with HIV-1.
2. (Original) The immunotoxin of claim 1, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.
3. (Original) The immunotoxin of claim 2, wherein said cytotoxin is a modified *Pseudomonas* exotoxin.
4. (Previously presented) The immunotoxin of claim 3, wherein said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL (KDEL = SEQ ID NO:9), and PE38REDL (RDEL = SEQ ID NO:10).
5. (Original) The immunotoxin of claim 4, wherein said modified *Pseudomonas* exotoxin is PE38.
6. (Original) The immunotoxin of claim 1, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

BEST AVAILABLE COPY

PATENT

Appl. No. 09/673,707

Amdt. dated October 12, 2004

Reply to Office Action of September 15, 2004

7. (Original) The immunotoxin of claim 6, wherein said antibody is a recombinantly expressed single-chain Fv.
8. (Original) The immunotoxin of claim 6, wherein said antibody is 3B3(Fv).
9. (Original) The immunotoxin of claim 1, wherein said immunotoxin is a fusion protein.
10. (Original) The immunotoxin of claim 1, wherein said immunotoxin is 3B3(Fv)-PE38.
11. (Original) The immunotoxin of claim 1, wherein said immunotoxin is suspended or dissolved in a pharmaceutically acceptable carrier or excipient.
- 12-18. Canceled.
19. (Withdrawn) A single chain Fv antibody having the binding specificity of 3B3.
20. (Withdrawn) The antibody of claim 19, wherein said antibody has the amino acid sequence of 3B3 or conservative substitutions thereof.
21. (Withdrawn) The antibody of claim 20, wherein said antibody is 3B3(Fv).
22. (Withdrawn) A nucleic acid that encodes a single chain Fv antibody having the binding specificity of 3B3.
23. (Withdrawn) The nucleic acid of claim 22, wherein said antibody has the amino acid sequence of 3B3 or conservative substitutions thereof.

PATENT

Appl. No. 09/673,707
Amdt. dated October 12, 2004
Reply to Office Action of September 15, 2004

24. (Withdrawn) The nucleic acid of claim 20, wherein said nucleic acid encodes the 3B3 antibody.

25-51. Canceled.

52. (Currently amended) A kit for killing cells that display a gp120 protein, said kit comprising a container containing an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity to the CD4 binding site of gp120 of 3B3 and a minimum binding affinity to gp-120 of 3B3, wherein said immunotoxin specifically binds to and kills mammalian cells infected with HIV-1.

53. (Original) The kit of claim 52, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

54. (Original) The kit of claim 53, wherein said cytotoxin is a modified *Pseudomonas* exotoxin.

55. (Original) The kit of claim 53, wherein said immunotoxin is 3B3(Fv) attached to a modified *Pseudomonas* exotoxin.

56. (Original) The kit of claim 55, wherein said immunotoxin is 3B3(Fv)-PE38.

57. (Currently amended) An immunotoxin of claim 1, wherein said immunotoxin is a disulfide-stabilized ("ds") FV ("~~ds~~Fv").

58. (Previously presented) An immunotoxin of claim 57, wherein said immunotoxin is 3B3dsFv-PE38.

PATENT

Appl. No. 09/673,707
Amdt. dated October 12, 2004
Reply to Office Action of September 15, 2004

59. (Withdrawn) A nucleic acid that encodes a single chain fusion protein, said nucleic acid comprising:

(a) a nucleic acid sequence that encodes a single-chain antibody having the binding specificity of 3B3; and

(b) a nucleic acid sequence that encodes a cytotoxin.

60. (Withdrawn) A nucleic acid of claim 59, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

61. (Withdrawn) A nucleic acid of claim 59, wherein said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL (KDEL = SEQ ID NO:9), and PE38REDL (RDEL = SEQ ID NO:10).

62. (Withdrawn) A nucleic acid of claim 61, wherein said modified *Pseudomonas* exotoxin is PE38.

63. (Withdrawn) A nucleic acid of claim 59, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

64. (Withdrawn) A nucleic acid of claim 63, wherein said antibody is a recombinantly expressed single chain Fv.

65. (Withdrawn) A nucleic acid of claim 63, wherein said antibody is a dsFv.

66. (Withdrawn) A nucleic acid of claim 63, wherein said antibody is 3B3(dsFv).

PATENT

Appl. No. 09/673,707

Amdt. dated October 12, 2004

Reply to Office Action of September 15, 2004

67. (Withdrawn) A nucleic acid of claim 59, wherein said fusion protein is 3B3dsFv-PE38 or 3B3(Fv)-PE38.

68. (Previously presented) A composition, said composition comprising:
a pharmaceutically acceptable carrier or excipient; and
an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody
having the binding specificity of 3B3.

69. (Previously presented) A composition of claim 68, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

70. (Previously presented) A composition of claim 69, in which said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL (KDEL = SEQ ID NO:9), and PE38REDL (RDEL = SEQ ID NO:10).

71. (Previously presented) A composition of claim 70, wherein said modified *Pseudomonas* exotoxin is PE38.

72. (Previously presented) A composition of claim 68, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

73. (Previously presented) A composition of claim 72, wherein said antibody is a recombinantly expressed single-chain Fv.

74. (Previously presented) A composition of claim 73, wherein said antibody is 3B3(Fv).

PATENT

Appl. No. 09/673,707

Amdt. dated October 12, 2004

Reply to Office Action of September 15, 2004

75. (Previously presented) A composition of claim 72, wherein said antibody is a dsFv.
76. (Previously presented) A composition of claim 75, wherein said antibody is 3B3(dsFv).
77. (Previously presented) A composition of claim 72, wherein said immunotoxin is a fusion protein.
78. (Previously presented) A composition of claim 77, wherein said immunotoxin is 3B3(Fv)-PE38.
79. (Withdrawn) A method of killing or inhibiting the growth of a cell displaying a gp120 protein or fragment thereof, said method comprising contacting said cell with an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3.
80. (Withdrawn) A method of claim 79, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.
81. (Withdrawn) A method of claim 80, wherein said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL (KDEL = SEQ ID NO:9), and PE38REDL (RDEL = SEQ ID NO:10).
82. (Withdrawn) A method of claim 81, wherein said modified *Pseudomonas* exotoxin is PE38.

Appl. No. 09/673,707

PATENT

Amdt. dated October 12, 2004

Reply to Office Action of September 15, 2004

83. (Withdrawn) A method of claim 79, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

84. (Withdrawn) A method of claim 83, wherein said antibody is a recombinantly expressed single-chain Fv.

85. (Withdrawn) A method of claim 83, wherein said antibody is 3B3(Fv).

86. (Withdrawn) A method of claim 83, wherein said antibody is a dsFv.

87. (Withdrawn) A method of claim 83, wherein said antibody is 3B3(dsFv).

88. (Withdrawn) A method of claim 83, wherein said immunotoxin is a fusion protein.

89. (Withdrawn) A method of claim 83, wherein said immunotoxin is 3B3(Fv)-PE38.

90. (Withdrawn) A method of killing or inhibiting the growth of cells bearing gp120 protein or fragment thereof, said method comprising administering to an organism containing said cells a composition comprising:

a pharmaceutically acceptable carrier or excipient; and

an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3 and minimum affinity of 3B3.

91. (Withdrawn) A method of claim 90, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

PATENT

Appl. No. 09/673,707
Amdt. dated October 12, 2004
Reply to Office Action of September 15, 2004

92. (Withdrawn) A method of claim 91, wherein said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL (KDEL = SEQ ID NO:9), and PE38REDL (RDEL = SEQ ID NO:10).

93. (Withdrawn) A method of claim 91, wherein said modified *Pseudomonas* exotoxin is PE38.

94. (Withdrawn) A method of claim 90, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

95. (Withdrawn) A method of claim 94, wherein said antibody is a recombinantly expressed single-chain Fv.

96. (Withdrawn) A method of claim 94, wherein said antibody is 3B3(Fv).

97. (Withdrawn) A method of claim 94, wherein said antibody is a dsFv.

98. (Withdrawn) A method of claim 97, wherein said antibody is 3B3(dsFv).

99. (Withdrawn) A method of claim 90, wherein said immunotoxin is a fusion protein.

100. (Withdrawn) A method of claim 99, wherein said immunotoxin is 3B3(Fv)-PE38.

101. (Withdrawn) A method of claim 90, further comprising administering to said organism a protease inhibitor.

PATENT

Appl. No. 09/673,707
Amdt. dated October 12, 2004
Reply to Office Action of September 15, 2004

102. (Withdrawn) A method of claim 90, further comprising administering to said organism a reverse transcriptase inhibitor.

103. (Withdrawn) A method of claim 90, further comprising administering to said organism both a protease inhibitor and a reverse transcriptase inhibitor and then withdrawing the reverse transcriptase inhibitor while maintaining protease inhibitor dosing during administration of said composition.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.